Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
genetically modified Neisseria lactamica 4xrNlac
- Development stage
- Unknown
- Lead developer
- University of Southampton
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Genetically modified Neisseria lactamica 4xrNlac (4xrNlac) is an experimental live bacterial challenge agent and recombinant vaccine candidate developed by the University of Southampton in collaboration with the UK Health Security Agency (UKHSA). It consists of a mixture of four genetically modified strains of the commensal bacterium *Neisseria lactamica*, each engineered to express two key surface antigens from the pathogenic bacterium *Neisseria meningitidis*: Factor H Binding Protein (FHbp) and Neisseria Adhesin A (NadA). Administered intranasally, 4xrNlac is designed to colonize the nasopharynx asymptomatically, mimicking natural carriage to elicit mucosal and systemic immune responses, including serum bactericidal antibodies, to prevent meningococcal infection and disease.
- Other names
- genetically modified Neisseria lactamicaGM-Nlacrecombinant Neisseria lactamica
02
Targets
CFH (Complement factor H)fHbp (Factor H-binding protein)NadA (Neisserial adhesin A)
Beyond the preview
Go deeper on genetically modified Neisseria lactamica 4xrNlac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on genetically modified Neisseria lactamica 4xrNlac.